AngioDynamics (ANGO) Tops Q3 EPS by 2c ; Offers Guidance

AngioDynamics (NASDAQ: ANGO) reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $78.42 million versus the consensus estimate of $76.71 million.

GUIDANCE:

AngioDynamics sees FY2026 EPS of ($0.30)-($0.23), versus the consensus of ($0.29). AngioDynamics sees FY2026 revenue of $313.5-315.5 million, versus the consensus of $312.9 million.

For earnings history and earnings-related data on AngioDynamics (ANGO) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• XP Inc eyes US banking license as next business step
• Four Tree Island Advisory calls DoubleDown $11.25 offer too low